Anti-Aging
MT-1
C₇₈H₁₁₁N₂₁O₁₉
Key Research Findings
- FDA Breakthrough Therapy designation and EMA approval for EPP under the name Scenesse.
- Selectively activates MC1R, producing eumelanin with minimal off-target melanocortin receptor activity.
- Clinical trials demonstrate significant reduction in phototoxic reactions in EPP patients.
- Depot implant formulation achieves sustained plasma levels for approximately 60 days.
Overview
MT-1 (Melanotan I, Afamelanotide) is a synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH) that selectively activates the MC1R melanocortin receptor. It has been extensively studied for its role in stimulating melanogenesis — the production of photoprotective eumelanin pigment — and is licensed in several countries as Scenesse for erythropoietic protoporphyria (EPP).
Mechanism of Action
MT-1 binds selectively to the melanocortin-1 receptor (MC1R) on melanocytes, activating adenylyl cyclase and increasing intracellular cAMP. This triggers the upregulation of tyrosinase and the melanogenic cascade, preferentially producing eumelanin — the darker, more UV-protective pigment — over pheomelanin. The resulting increase in skin pigmentation reduces photosensitivity.
Research Effects
Melanogenesis
Extensive ResearchRobust clinical and in vitro evidence for MC1R-mediated eumelanin production; the basis for its approved therapeutic use in EPP.
Photoprotection
Extensive ResearchApproved clinical evidence shows increased photoprotective melanin pigmentation reduces UV-induced photosensitivity in EPP patients.
Skin Pigmentation
Moderate ResearchResearch in healthy subjects demonstrates dose-dependent increase in skin pigmentation without sun exposure required.
Anti-inflammatory
Preliminary ResearchMC1R activation is associated with anti-inflammatory cytokine modulation; early studies suggest possible utility in inflammatory skin conditions.
Research Purposes Only — All information on this page is provided for scientific research purposes only. This product is not intended for human consumption, diagnosis, treatment, or prevention of any disease.
Quick Facts
Research Status Key
Related Peptides
Anti-Aging
MT-2
MT-2 (Melanotan II) is a cyclic, non-selective melanocortin receptor agonist developed as a shorter, more potent analogue of MT-1. It activates multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R) and has been studied for its diverse effects on pigmentation, energy homeostasis, and physiological regulation.
Learn More →
Anti-Aging
PT-141
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin agonist derived from MT-2, distinguished by its free carboxyl terminus. It is the first and only FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi, and is studied for its central nervous system-mediated effects.
Learn More →
Anti-Aging
Epitalon
Epitalon (Epithalon) is a synthetic tetrapeptide derived from the pineal gland peptide Epithalamin, developed by Professor Vladimir Khavinson in Russia. It is studied primarily for its ability to activate telomerase and elongate telomeres, positioning it as a key research compound in the biology of ageing.
Learn More →